Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 34

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 34
---
 D-1 |
| Annex E FAIRNESS OPINION AND VALUATION REPORTS OF MOORE FINANCIAL CONSULTING   |     |  E-1 |
| ANNEX F FINANCIAL STATEMENTS OF NLS PHARMACEUTICS LTD. AS OF DECEMBER 31, 2024 |     |  F-1 |
| ANNEX G FINANCIAL STATEMENTS OF KADIMASTEM LTD. AS OF DECEMBER 31, 2024        |     |  G-1 |
| ANNEX H PROXY CARD                                                             |     |  H-1 |

ii QUESTIONS AND ANSWERS ABOUT THE PROPOSALS The following section provides answers to frequently asked questions that you, as an NLS or Kadimastem shareholder, may have regarding the Merger, the Merger Agreement and other matters to be acted upon at the NLS Meeting and with respect to the NLS Ordinary Shares to be received in the Merger. We urge you to carefully read the remainder of this proxy statement/prospectus because the information in this section does not provide all the information that might be important to you with respect to the Merger, the Merger Agreement and other matters relating to the NLS Meeting or with respect to NLS Common Shares. Additional important information is contained in the cross -referencedsections, the annexes to, and the sections and documents incorporated by reference in, this proxy statement/prospectus. Q.Why am I receiving this proxy statement/prospectus? You are receiving this proxy statement/prospectus because you have been identified as a shareholder of NLS as of the record date, and you are entitled to vote at the NLS Meeting to approve the matters described in this proxy statement/prospectus, NLS and Kadimastem have entered into the Merger Agreement that is described in this proxy statement/prospectus. Pursuant to the Merger Agreement, and amendments thereto, which is attached as Annex A hereto, upon the terms and subject to the conditions set forth therein, at the Closing, (i) Merger Sub will merge with and into Kadimastem, with Kadimastem as the surviving company, and (ii) at the Effective Time, each Kadimastem Ordinary Share will be exchanged for and automatically converted into the right to receive from NLS that certain number of fully paid and nonassessable NLS Common Shares as calculated in accordance with the terms of the Merger Agreement, or the